Cochrane
Systematic review
Jun 2026
Patients and professionals
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics
Biologics and newer medicines
Research
Jargon explained
network meta-analysis
relative risk
number needed to treat
biosimilar
NICE
Guideline
May 2010
For professionals
NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.
Topics
Biologics and newer medicines
Medicines
Jargon explained
anti-TNF
biosimilar
conventional therapy
severe active Crohn's disease
NHS
Web page
Aug 2026
For patients
The NHS medicine guide to adalimumab, listing brands such as Amgevita, Humira, Imraldi and Yuflyma. It explains that it treats autoimmune conditions including Crohn's disease, is usually started by a specialist after other medicines have not worked, and needs regular blood tests.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
autoimmune condition
biosimilar
NHS England
Web page
Patients and professionals
NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biosimilar
originator medicine
switching
Crohn's & Colitis UK
Guide
Jun 2024
For patients
A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
infusion
subcutaneous
biosimilar
drug levels
antibodies
Crohn's & Colitis UK
Guide
Sep 2024
For patients
A guide to adalimumab, an anti-TNF biologic you inject under your skin with a pen or syringe. It explains that Humira was the first brand and Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma are biosimilars, and that blood tests may check drug and antibody levels.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
biosimilar
antibodies
subcutaneous injection
Crohn's & Colitis UK
Guide
For patients
A guide to ustekinumab, an interleukin inhibitor that blocks IL-12 and IL-23. Stelara was the first brand and several biosimilars now exist. The first dose is a drip, then injections under the skin; the page covers trial results and side effects.
Topics
Biologics and newer medicines
Jargon explained
interleukin inhibitor
IL-12
IL-23
biosimilar
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
Crohn's & Colitis UK
Guide
For patients
Explains the basics behind IBD medicines: active and inactive ingredients, brand and generic names, and what biosimilars are. It uses infliximab as an example, explaining that biosimilars meet strict standards and you may sometimes be moved to a different one.
Topics
Medicines
Biologics and newer medicines
Jargon explained
biosimilar
originator
generic
Royal Free London NHS Foundation Trust
Leaflet
Aug 2025
For patients
A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.
Topics
Biologics and newer medicines
Jargon explained
biologic
infusion
biosimilar
Cochrane (via PMC)
Systematic review
Nov 2023
Patients and professionals
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics
Biologics and newer medicines
Research
Jargon explained
combination therapy
purine analogue
biosimilar
CT-P13
Gastroenterology
Study
Jan 2007
Patients and professionals
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics
Biologics and newer medicines
Jargon explained
maintenance
remission
CDAI
placebo